Merck to acquire cCAM Biotherapeutics, Israel’s cancer cure solution company, for $605m

US-based Merck has signed an agreement to acquire Israel-based biopharmaceutical firm cCAM Biotherapeutics for around $605m.

As part of the deal, Merck, through its subsidiary, will purchase all outstanding stock of cCAM for $95m. The deal will also allow cCAM shareholders to receive up to $510m based on the attainment of certain clinical development, regulatory and commercial milestones.

Merck Research Laboratories president Dr Roger Perlmutter said: “We continue to strengthen our portfolio of immunotherapeutic candidates through strategic collaborations and acquisitions.

See more

cCAM’s Website

2015-08-05T14:12:37+00:00August 5th, 2015|Medical|0 Comments